Leap Therapeutics is a biotechnology business based in the US. Leap Therapeutics shares (LPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Leap Therapeutics employs 54 staff and has a trailing 12-month revenue of around $375,000.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $2.11 |
|---|---|
| 52-week range | $1.24 - $5.00 |
| 50-day moving average | $2.25 |
| 200-day moving average | $2.56 |
| Wall St. target price | $11.38 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.25 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.11 from 2024-07-22
| 1 week (2024-07-17) | -4.09% |
|---|---|
| 1 month (2024-06-24) | 12.23% |
| 3 months (2024-04-24) | -35.87% |
| 6 months (2024-01-24) | -20.68% |
| 1 year (2023-07-24) | -28.47% |
|---|---|
| 2 years (2022-07-22) | 93.58% |
| 3 years (2021-07-23) | 52.90% |
| 5 years (2019-07-24) | 9.33% |
Valuing Leap Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Leap Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Leap Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Leap Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $375,000 |
|---|---|
| Gross profit TTM | $1.5 million |
| Return on assets TTM | -44.12% |
| Return on equity TTM | -74.43% |
| Profit margin | 0% |
| Book value | $1.85 |
| Market Capitalization | $79.2 million |
TTM: trailing 12 months
We're not expecting Leap Therapeutics to pay a dividend over the next 12 months.
Leap Therapeutics's shares were split on a 1:10 basis on 20 June 2023. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Leap Therapeutics shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Leap Therapeutics shares which in turn could have impacted Leap Therapeutics's share price.
Over the last 12 months, Leap Therapeutics's shares have ranged in value from as little as $1.235 up to $5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Leap Therapeutics's is 0.317. This would suggest that Leap Therapeutics's shares are less volatile than average (for this exchange).
Leap Therapeutics, Inc. , a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18. 2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Trade commission-free stocks and ETFs with Opto, and stay ahead by spotting emerging trends through thematic investing.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Spot Ethereum ETFs might soon be approved. Here’s how to invest if and when they become available to trade.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.